

**WORLD HEALTH ORGANIZATION
GLOBAL PROGRAMME TO ELIMINATE
LYMPHATIC FILARIASIS**

**LYMPHATIC FILARIASIS:
MANAGING MORBIDITY AND
PREVENTING DISABILITY**

LYMPHATIC FILARIASIS

**AN AIDE-MÉMOIRE
FOR NATIONAL PROGRAMME MANAGERS**



**World Health
Organization**

**WORLD HEALTH ORGANIZATION
GLOBAL PROGRAMME TO ELIMINATE
LYMPHATIC FILARIASIS**

**LYMPHATIC FILARIASIS:
MANAGING MORBIDITY AND
PREVENTING DISABILITY**

LYMPHATIC FILARIASIS

**AN AIDE-MÉMOIRE
FOR NATIONAL PROGRAMME MANAGERS**



**World Health
Organization**

WHO Library Cataloguing-in-Publication Data

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers.

1.Elephantiasis, Filarial — epidemiology. 2.Elephantiasis, Filarial - complications. 3.Endemic diseases — prevention and control. 4.Disability evaluation. 5.National health programs. .I.World Health Organization. II.Global Programme to Eliminate Lymphatic Filariasis.

ISBN 978 92 4 150529 1

(NLM classification: WC 880)

© World Health Organization 2013

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications —whether for sale or for non-commercial distribution— should be addressed to WHO Press through the WHO web site (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed in France.

WHO/HTM/NTD/PCT/2013.7



Contents

Acknowledgements	v
Glossary	vii
Summary	ix
SECTION 1. INTRODUCTION	1
1.1 Eliminating lymphatic filariasis	1
1.1.1 Background	1
1.1.2 Integrating elimination of lymphatic filariasis into the control of neglected tropical diseases	4
1.2 Morbidity associated with lymphatic filariasis	5
1.2.1 Background and epidemiology	5
1.2.2 Signs and symptoms	6
1.2.3 Socioeconomic burden	7
1.2.4 Associated disability	7
1.3 Tools for managing morbidity and preventing disability	
1.3.1 Managing acute dermatolymphangioadenitis and acute attacks	9
1.3.2 Managing lymphoedema and elephantiasis	9
1.3.3 Managing hydrocoele	10
SECTION 2. MMDP WITHIN THE GLOBAL PROGRAMME TO ELIMINATE LYMPHATIC FILARIASIS	13
2.1 Why manage morbidity and prevent disability?	13
2.2 What is MMDP?	14
2.3 Goals and aim of MMDP?	14
2.4 Strategic planning	15
2.5 What will success look like?	15

SECTION 3. PLANNING MMDP IN A NATIONAL PROGRAMME 17

3.1 Policy and guiding principles	17
3.2 Strategic planning and implementation	18
3.2.1 Situation analysis	18
3.2.2 Implementation policy and plan	21
3.2.3 Operational activities	22
3.3 Monitoring and evaluation	32
3.3.1 National monitoring and evaluation plan	33
3.3.2 Annual reporting to the Global Programme	36

SECTION 4. REFERENCES 39

ANNEXES 43

Annex 1. Stages of lymphoedema and elephantiasis	43
Annex 2. Algorithm for deciding on the management of acute dermatolymphangioadenitis	44
Annex 3. Information to be collected for a situation analysis	45
Annex 4. Example of steps for home-based management of lymphoedema and elephantiasis	47
Annex 5. Examples of individual recording, follow-up and monitoring forms	49
Annex 6. Example of monitoring and evaluation at reporting unit level	51
Annex 7. Examples of reporting forms from health centre to reporting unit and from reporting unit to national level	53

Acknowledgements

Lymphatic filariasis: managing morbidity and preventing disability: an aide-mémoire for national programme managers was prepared under the supervision of Dr Lorenzo Savioli, Director, Department of Control of Neglected Tropical Diseases, WHO.

WHO acknowledges all those people who contributed to this document, in particular:

Dr David Addiss (Children Without Worms, USA), Dr Steve Ault (WHO Regional Office for the Americas), Dr Riadh Ben-Ismaïl (WHO Regional Office for the Eastern Mediterranean), Ms Molly Brady (RTI International), Professor Moses Bockarie (Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, England), Dr Mark Bradley (GlaxoSmithKline), Dr Eva-Maria Chistophel (WHO Regional Office for the Western Pacific), Dr Georges-Pierre Capuano (Consultant), Dr Aditya Prasad Dash (WHO Regional Office for South-East Asia), Dr LeAnne Fox (United States Centers for Disease Control and Prevention), Dr Mary-Jo Geyer (University of Pittsburgh, USA), Dr Patricia Graves (James Cook University, Australia), Dr John Gyapong (University of Ghana), Dr Ralph Henderson (Task Force for Global Health, USA), Dr Adrian Hopkins (Mectizan Donation Program, USA), Dr Julie Jacobson (Bill & Melinda Gates Foundation, USA), Dr Christopher King (Case Western Reserve University, USA), Dr Kaliannagounder Krishnamoorthy (Vector Control Research Centre, India), Dr Suma Krishnasastri (T.D. Medical College Hospital, India), Dr Dominique Kyelem (Task Force for Global Health, USA), Dr Patrick Lammie (United States Centers for Disease Control and Prevention), Professor David Molyneux (Liverpool School of Tropical Medicine, England), Dr Sabine Susanne Mand (University of Bonn Medical Centre, Germany), Dr Sunny Doodu Mante (Military Hospital, Ghana), Dr Adiele Onyeze (WHO

Regional Office for Africa), Dr Eric Ottesen (Task Force for Global Health, USA), Dr Kapa Ramaiah (Consultant), Dr Reda Ramzy (National Nutrition Institute, Egypt), Dr Frank Richards (The Carter Center, USA), Professor Terence Ryan (Task Force Skin Care for All), Ms Angela Weaver (United States Agency for International Development) and Professor Gary Weil (Washington University School of Medicine, USA).

Grateful acknowledgement is also extended to Dr Pierre Brantus (Handicap International, France), Dr Vasanthapuram Kumaraswami (Task Force for Global Health) and Professor Charles Mackenzie (Michigan State University, USA), who improved and edited the document in consultation with Dr Kazuyo Ichimori (Focal Point for Lymphatic Filariasis Elimination, WHO).

预览已结束，完整报告链接和二维

<https://www.yunbaogao.cn/report/index/report?report>